AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34837553 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) therapy set at 40 L/min and titrated based on improvement in ROX index and patient tolerance.
Number of subjects: 49
Study 34837553 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC flow set at 45 L/min at enrollment.
Number of subjects: 49
Study 34837882 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar depression
Number of subjects: 240
Study 34837882 — intervention group
Group type: COMPARATOR
Intervention: Unipolar depression
Number of subjects: 240
Study 34837882 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 240
Study 34837994 — intervention group
Group type: EXPERIMENTAL
Intervention: Living at home
Number of subjects: 15
Study 34837994 — intervention group
Group type: EXPERIMENTAL
Intervention: Living at a nursing home
Number of subjects: 15
Study 34837994 — intervention group
Group type: EXPERIMENTAL
Intervention: Time after death
Number of subjects: 15
Study 34838101 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Care Specialist (LCS) intervention
Number of subjects: 200
Study 34838101 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care control
Number of subjects: 200
Study 34838109 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia (OFA) protocol using clonidine, magnesium sulfate, ketamine, and lidocaine
Number of subjects: 140
Study 34838109 — intervention group
Group type: COMPARATOR
Intervention: Standard anesthesia protocol based on opioid use
Number of subjects: 140
Study 34838109 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia (OFA) protocol
Number of subjects: 140
Study 34838114 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine (0.2 mg/kg)
Number of subjects: 210
Study 34838114 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine (0.4 mg/kg)
Number of subjects: 210
Study 34838114 — intervention group
Group type: COMPARATOR
Intervention: Control treatment without S-ketamine
Number of subjects: 210
Study 34838125 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT) and work-focused interventions
Number of subjects: 240
Study 34838125 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 240
Study 34838325 — intervention group
Group type: EXPERIMENTAL
Intervention: Guardant360 CDx plasma testing for KRAS p.G12C mutations
Number of subjects: 126
Study 34838325 — intervention group
Group type: COMPARATOR
Intervention: Therascreen® KRAS RGQ PCR kit tissue testing
Number of subjects: 126
Study 34838325 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rate (ORR)
Number of subjects: 126
Study 34838464 — intervention group
Group type: EXPERIMENTAL
Intervention: PPM (Prosthesis-Patient Mismatch)
Number of subjects: 1101
Study 34838464 — intervention group
Group type: COMPARATOR
Intervention: PPM
Number of subjects: 1101
Study 34838518 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT in Asian patients with QRSd <150 ms (n=71)
Number of subjects: 934
Study 34838518 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT in Asian patients with QRSd ≥150 ms (n=180)
Number of subjects: 934
Study 34838518 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall CRT response in Asians (n=251)
Number of subjects: 934
Study 34838518 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure events and cardiac deaths in Asians
Number of subjects: 934
Study 34838518 — intervention group
Group type: COMPARATOR
Intervention: CRT response in non-Asian patients with QRSd <150 ms (n=248)
Number of subjects: 934
Study 34838518 — intervention group
Group type: COMPARATOR
Intervention: CRT response in non-Asian patients with QRSd ≥150 ms (n=435)
Number of subjects: 934
Study 34838717 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HPV prevalence measured using a commercially available PCR DNA test.
Number of subjects: 7877
Study 34838717 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up every 6 months for 24 months in the US.
Number of subjects: 7877
Study 34838718 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccination
Number of subjects: 0
Study 34838718 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34839011 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant Starch (RS) in PD patients (PD + RS)
Number of subjects: 87
Study 34839011 — intervention group
Group type: COMPARATOR
Intervention: Resistant Starch (RS) in control subjects
Number of subjects: 87
Study 34839011 — intervention group
Group type: COMPARATOR
Intervention: Dietary instructions in PD patients
Number of subjects: 87
Study 34839054 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine followed by rapamycin (10 days of decitabine followed by 12 days of rapamycin in cycle 1 and 5 days of decitabine followed by 17 days of rapamycin in subsequent cycles)
Number of subjects: 24
Study 34839054 — intervention group
Group type: COMPARATOR
Intervention: Decitabine alone (historical control)
Number of subjects: 24
Study 34839054 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine followed by rapamycin (in de novo group)
Number of subjects: 24
Study 34839055 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intensive chemotherapy
Number of subjects: 104
Study 34839060 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerene cryotherapy device
Number of subjects: 230
Study 34839199 — intervention group
Group type: EXPERIMENTAL
Intervention: EMI-137 (0.13 mg/kg) administered intravenously 1-3 hours before surgery
Number of subjects: 9
Study 34839196 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting stress at hospital discharge
Number of subjects: 158
Study 34839196 — intervention group
Group type: EXPERIMENTAL
Intervention: Education at hospital discharge
Number of subjects: 158
Study 34839196 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant's medication number at hospital discharge
Number of subjects: 158
Study 34839196 — intervention group
Group type: EXPERIMENTAL
Intervention: Insurance type at hospital discharge
Number of subjects: 158
Study 34839196 — intervention group
Group type: EXPERIMENTAL
Intervention: Medications number at hospital discharge
Number of subjects: 158
Study 34839196 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube-assisted feeding at hospital discharge
Number of subjects: 158
Study 34839196 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting stress at 4 months
Number of subjects: 158
Study 34839196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnicity at 4 months
Number of subjects: 158
Study 34839196 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of ED visits at 4 months
Number of subjects: 158
Study 34839196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiologist visits at 4 months
Number of subjects: 158
Study 34839196 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ventricle physiology at 4 months
Number of subjects: 158
Study 34839196 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of children at 4 months
Number of subjects: 158
Study 34839268 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 167
Study 34839268 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 167
Study 34839425 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Breast Reconstruction (IBR)
Number of subjects: 38
Study 34839425 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed Breast Reconstruction (DBR)
Number of subjects: 38
Study 34839425 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Flap Reconstruction
Number of subjects: 38
Study 34839425 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant Reconstruction
Number of subjects: 38
Study 34839447 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungal keratitis treatment
Number of subjects: 150
Study 34840296 — intervention group
Group type: EXPERIMENTAL
Intervention: Unroofing curettage
Number of subjects: 278
Study 34840296 — intervention group
Group type: COMPARATOR
Intervention: Modified Limberg flap
Number of subjects: 278
Study 34840564 — intervention group
Group type: EXPERIMENTAL
Intervention: Characteristics of skin and hair of pregnant women
Number of subjects: 0
Study 34840564 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin microbiome interactions
Number of subjects: 0
Study 34840651 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutathione supplement (L-glutathione, ascorbic acid, alpha-lipoic acid, zinc as zinc aspartate)
Number of subjects: 83
Study 34840651 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 83
Study 34840720 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib (0.1-2.0 mg once daily)
Number of subjects: 33
Study 34840869 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time nurse interpretation of quantitative EEG (qEEG)
Number of subjects: 109
Study 34840869 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse time to seizure detection
Number of subjects: 109
Study 34840869 — intervention group
Group type: EXPERIMENTAL
Intervention: Inaccurate nurse interpretation
Number of subjects: 109
Study 34840869 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall performance of nurse interpretation of qEEG
Number of subjects: 109
Study 34841093 — intervention group
Group type: EXPERIMENTAL
Intervention: PIRATES approach (intensity-modulated proton therapy, mid-treatment hybrid hyper-fractionation, MRI-guided mid-treatment boost volume adaptation, iso-effective restricted organ-at-risk dosing)
Number of subjects: 0
Study 34841093 — intervention group
Group type: EXPERIMENTAL
Intervention: PIRATES approach
Number of subjects: 0
Study 34841420 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Telehealth for HIV care during COVID-19
Number of subjects: 0
Study 34841420 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34841462 — intervention group
Group type: EXPERIMENTAL
Intervention: Short, fully hydroxyapatite-coated titanium stem (collared and collarless versions)
Number of subjects: 50
Study 34841945 — intervention group
Group type: EXPERIMENTAL
Intervention: Streamlined Care (rapid linkage to care and ART start, 3-monthly refills, viral load counseling, patient-centered care provision)
Number of subjects: 0
Study 34842060 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual group therapy intervention (8 sessions over 4 weeks)
Number of subjects: 20
Study 34842444 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleaner-burning stove intervention
Number of subjects: 1144
Study 34842444 — intervention group
Group type: COMPARATOR
Intervention: Higher early life HAP exposure
Number of subjects: 1144
Study 34842538 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media intervention (monitoring cancer-specific posts on Twitter)
Number of subjects: 434
Study 34842538 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media intervention (engagement with outreach messages)
Number of subjects: 434
Study 34842538 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media intervention (request for more information)
Number of subjects: 434
Study 34842538 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media intervention (setup of prescreening)
Number of subjects: 434
Study 34842538 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media intervention (transfer for further screening)
Number of subjects: 434
Study 34842546 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote GDMT titration intervention
Number of subjects: 16
Study 34842549 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week digital self-compassion intervention
Number of subjects: 0
Study 34842549 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 34842557 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive models built using methods from computational models of decision-making, combining objective data from a fitness tracker with personality traits and modeling from decision-making games delivered via a mobile app
Number of subjects: 200
Study 34842557 — intervention group
Group type: EXPERIMENTAL
Intervention: Iowa Gambling Task administered via a web app
Number of subjects: 200
Study 34842563 — intervention group
Group type: EXPERIMENTAL
Intervention: PARENT intervention (Parent Coach-led model of well-child care)
Number of subjects: 916
Study 34843044 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapanisertib (3 mg QD)
Number of subjects: 28
Study 34843044 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapanisertib (QD arm)
Number of subjects: 28
Study 34843044 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapanisertib (QW arm)
Number of subjects: 28
Study 34843044 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Number of subjects: 28
Study 34843370 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based attention module
Number of subjects: 0
Study 34843370 — intervention group
Group type: COMPARATOR
Intervention: Other training modules (not specified)
Number of subjects: 0
Study 34843401 — intervention group
Group type: EXPERIMENTAL
Intervention: Poziotinib (16 mg) once daily
Number of subjects: 90
Study 34843469 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional-dose 17DD-YF vaccine in ARD patients
Number of subjects: 318
Study 34843529 — intervention group
Group type: EXPERIMENTAL
Intervention: HCF-level stigma-reduction intervention
Number of subjects: 216
Study 34843529 — intervention group
Group type: COMPARATOR
Intervention: Standard of care control arm
Number of subjects: 216
Study 34843602 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoviral vector immunization
Number of subjects: 0
Study 34843602 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA/rAd5 and rAd35/rAd5 regimen
Number of subjects: 0
Study 34843602 — intervention group
Group type: COMPARATOR
Intervention: Pox-viral vectors
Number of subjects: 0
Study 34843666 — intervention group
Group type: EXPERIMENTAL
Intervention: pr/pb CAPA
Number of subjects: 509
Study 34843666 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >62 years
Number of subjects: 509
Study 34843666 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with dexamethasone and anti-IL-6
Number of subjects: 509
Study 34843666 — intervention group
Group type: EXPERIMENTAL
Intervention: Long duration of mechanical ventilation (>14 days)
Number of subjects: 509
Study 34843666 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ICU mortality in patients with pr/pb CAPA
Number of subjects: 509
Study 34843666 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >62 years (adjusted for candidaemia)
Number of subjects: 509
Study 34843666 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid organ transplantation (adjusted for candidaemia)
Number of subjects: 509
Study 34843666 — intervention group
Group type: EXPERIMENTAL
Intervention: pr/pb CAPA (adjusted for candidaemia)
Number of subjects: 509
Study 34843666 — intervention group
Group type: EXPERIMENTAL
Intervention: Other pr/pb IFIs
Number of subjects: 509
Study 34844152 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD-PRS (Polygenic Risk Score for Major Depressive Disorder)
Number of subjects: 3637
Study 34844152 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD-PRS
Number of subjects: 3637
Study 34844152 — intervention group
Group type: EXPERIMENTAL
Intervention: SCZ-PRS (Polygenic Risk Score for Schizophrenia)
Number of subjects: 3637
Study 34844255 — intervention group
Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 102
Study 34844283 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy guided by continuous glucose monitoring systems (CGMS)
Number of subjects: 0
Study 34844283 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy guided by other forms of glucose data collection
Number of subjects: 0
Study 34844422 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hyperglycemia (serum glucose levels ≥140 mg/dL-<180)
Number of subjects: 1000
Study 34844422 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hyperglycemia (serum glucose levels ≥180 mg/dL)
Number of subjects: 1000
Study 34844422 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent hyperglycemia (either moderate or severe)
Number of subjects: 1000
Study 34844606 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intakes of vitamin C
Number of subjects: 7766
Study 34844606 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intakes of vitamin B9
Number of subjects: 7766
Study 34844606 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intakes of vitamin K
Number of subjects: 7766
Study 34844606 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intakes of fibers
Number of subjects: 7766
Study 34844606 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intakes of fruit and vegetables
Number of subjects: 7766
Study 34844606 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intakes of calcium
Number of subjects: 7766
Study 34844606 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intakes of dairy products
Number of subjects: 7766
Study 34844641 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression stockings
Number of subjects: 225
Study 34844641 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplements
Number of subjects: 225
Study 34844641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 34844770 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 120 mg (LAN 120 mg)
Number of subjects: 52
Study 34844868 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access (RA)
Number of subjects: 3137
Study 34844868 — intervention group
Group type: COMPARATOR
Intervention: Femoral access (FA)
Number of subjects: 3137
Study 34844977 — intervention group
Group type: EXPERIMENTAL
Intervention: Etigilimab alone (0.3, 1.0, 3.0, 10.0, 20.0 mg/kg intravenously)
Number of subjects: 33
Study 34844977 — intervention group
Group type: EXPERIMENTAL
Intervention: Etigilimab in combination with nivolumab (3.0, 10.0, 20.0 mg/kg etigilimab and 240 mg nivolumab)
Number of subjects: 33
Study 34844977 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events reported in Phase 1a
Number of subjects: 33
Study 34844977 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events reported in Phase 1b
Number of subjects: 33
Study 34844980 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 0
Study 34844980 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib + PD-1 checkpoint inhibitor
Number of subjects: 0
Study 34844993 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Frequency 10-kHz Spinal Cord Stimulation
Number of subjects: 0
Study 34844993 — intervention group
Group type: COMPARATOR
Intervention: Conventional Treatments
Number of subjects: 0
Study 34845071 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1,200 mg/m²
Number of subjects: 0
Study 34845071 — intervention group
Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 0
Study 34845080 — intervention group
Group type: EXPERIMENTAL
Intervention: 52-pathogen TaqMan array card (TAC)
Number of subjects: 100
Study 34845082 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV10 in a 0+1 schedule (at 12 months)
Number of subjects: 2500
Study 34845082 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV10 in a 1+1 schedule (at 2 and 12 months)
Number of subjects: 2500
Study 34845082 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 in a 0+1 schedule (at 12 months)
Number of subjects: 2500
Study 34845082 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 in a 1+1 schedule (at 2 and 12 months)
Number of subjects: 2500
Study 34845082 — intervention group
Group type: COMPARATOR
Intervention: Single dose of PCV10 at 24 months (Control group)
Number of subjects: 2500
Study 34845167 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-operative red blood cell transfusion
Number of subjects: 5609
Study 34845300 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab intravitreal injections in vitrectomized eyes
Number of subjects: 46
Study 34845300 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab intravitreal injections in non-vitrectomized eyes
Number of subjects: 46
Study 34845300 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab intravitreal injections (both groups)
Number of subjects: 46
Study 34845532 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor sleep efficiency
Number of subjects: 953
Study 34845532 — intervention group
Group type: EXPERIMENTAL
Intervention: Later bedtime routines
Number of subjects: 953
Study 34845532 — intervention group
Group type: EXPERIMENTAL
Intervention: Deviation from usual sleep pattern
Number of subjects: 953
Study 34845532 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal type
Number of subjects: 953
Study 34845569 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway Meetings for Class I (Crisis, Imminent Risk)
Number of subjects: 0
Study 34845569 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway Meetings for Class II (Crisis, Non-Imminent Risk)
Number of subjects: 0
Study 34845868 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (1,000-2,000 mg daily in two divided doses during CCRT and adjuvant chemotherapy)
Number of subjects: 73
Study 34845917 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised clustering (using generalized low rank modeling and K-means cluster analysis)
Number of subjects: 1329
Study 34845917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 1 (oldest/most comorbid)
Number of subjects: 1329
Study 34845917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 2 (youngest/multiethnic)
Number of subjects: 1329
Study 34845917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 4 (middle-aged/healthiest behaviors)
Number of subjects: 1329
Study 34845917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 3 (middle-aged/lowest medication adherence)
Number of subjects: 1329
Study 34845917 — intervention group
Group type: COMPARATOR
Intervention: Cluster membership vs. pooled cohort equations
Number of subjects: 1329
Study 34845924 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of EPA+DHA >200 mg/d
Number of subjects: 4067
Study 34845924 — intervention group
Group type: COMPARATOR
Intervention: Dietary intake of EPA+DHA ≤50 mg/d
Number of subjects: 4067
Study 34845924 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of EPA+DHA per 100 mg/d
Number of subjects: 4067
Study 34845924 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish consumption
Number of subjects: 4067